Alex (Aleksandrs Zavoronkovs) ZhavoronkovFounder

United Arab Emirates - Dubai

I do not use LinkedIn as much as I should. Please shoot an email if you would like to reach me.

Insilico Medicine (www.insilico.com) is a global clinical-stage AI-powered drug discovery and development company founded in 2014. Until 2019 it was an AI-first drug discovery company with most of the team focused exclusively on developing and applying deep learning methods to drug discovery. Insilico is the original inventor of multiple drug discovery technologies with multiple granted and pending patents in biomarker development and generative chemistry. In 2019 the company started working on its own therapeutic programs focusing predominantly on immunology, oncology, fibrosis, and CNS. It also made its industrial-strength target discovery platforms (PandaOmics) and generative chemistry (Chemistry42) platforms available for licensing and partnering. It raised over $300 million from expert healthcare, biotechnology, and technology investors, and entered Phase I clinical trials with the novel target discovered using AI and novel molecule designed using AI.
https://insilico.com/phase1

Publication record:
http://www.ncbi.nlm.nih.gov/pubmed/?term=zhavoronkov+a
https://scholar.google.com/citations?user=8Icccp0AAAAJ&hl=en

My book is out in English, Japanese, Chinese, and Polish:
"The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy", Palgrave Macmillan, NY, 2013
http://www.amazon.com/The-Ageless-Generation-Biomedicine-Transform/dp/0230342205/

Email: alex@insilico.com
FB: /biogerontology
Twitter: @biogerontology
WeChat ID: biogerontology